Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
MATTHEW GALGANI

IBD 50 Stock Testing Buy Point After 38% One-Day Jump

After gapping up to a nearly 38% gain in a single day on earnings last month, Medpace continues to test a new buy point. The provider of clinical research-based drug and medical device development services has landed a spot on the IBD 50 and IBD Leaderboard.

Medpace also earns placement on the latest list of new buys by the best mutual funds. Plus, 27 funds with an "A+" rating from IBD own shares in the company, which has grown from its founding in 1992 to over 4,800 employees across 41 countries.

With a 96 Composite Rating, MEDP stock scores top billing among its peers in the Medical-Research Equipment/Services group. Boosted by a 0% debt-to-equity ratio, the company has an "A" SMR Rating in Stock Checkup, which tracks sales growth, profit margins and return on equity.

Q3 earnings rose 59%, with revenue up 30% to $383.7 million. Analysts see 35% EPS growth in Q4.

Over the last three years, Medpace has generated average annual EPS gains of 32%. Wall Street forecasts 45% earnings growth for the full year.

Medpace Tests New Breakout

In a sign of sustained strength, MEDP stock has held the bulk of its gains from last month's massive gap-up. Volume on the Oct. 24 surge was a powerful 703% above average.

As you like to see after such a jump, trading has tightened up as investors digest those gains, hopefully in preparation for a continued rise. The relative strength line continues to hold right around its 52-week high.

Medpace is now moving back up to the 231.10 buy point it briefly cleared on Oct. 26. The stock fell more than 8% below the entry, which was a sell signal. But the constructive action lately resembles a handle formation. So, 235.82 could be viewed as another buy point.

The 50-day moving average has perked up again but has a long way to go to catch up with the actual stock price action.

As Medpace approaches the 231.10 entry, look for volume to come in at least 40% higher than normal on any breakout attempt to confirm demand for the move.

Follow Matthew Galgani on Twitter at @IBD_MGalgani.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.